VEGFR and Its Receptors: Structure, Function and Therapeutic Implications

Target Name: Vascular endothelial growth factor receptor (VEGFR)

NCBI ID: P6259

Other Name(s): Vascular endothelial growth factor receptor | VEGFR | VEGFR (nonspecified subtype)

VEGFR and Its Receptors: Structure, Function and Therapeutic Implications

Vascular endothelial growth factor receptor (VEGFR), also known as Kirsten, is a transmembrane protein that is involved in cell signaling pathways, including angiogenesis, vascular remodeling, and cancer progression. It is a member of the tyrosine kinase family and consists of four subtypes, including VEGFR1, VEGFR2, VEGFR3, and VEGFR4. The VEGFR subtypes have different levels of expression and function, and VEGFR has been implicated in various diseases, including cancer, cardiovascular disease, and neurodegenerative disorders.

VEGFR is involved in the regulation of cell proliferation, differentiation, and survival, and its activity is regulated by various factors, including tyrosine kinase inhibitors, growth factors, growth factor receptor tyrosine kinase inhibitors, etc. The function and activity of VEGFR are affected by multiple signaling pathways, including cell cycle, growth, cell proliferation, apoptosis, angiogenesis, etc.

The key molecule in the VEGFR signaling pathway is EGFR, a common tyrosine kinase that is overexpressed in many tumors. Overexpression of EGFR leads to the increase of vascular endothelial growth factor (VEGF), an important growth factor that promotes angiogenesis and tumor growth. In addition, EGFR also binds to PDGF receptors, further promoting tumor growth.

Among the four subtypes of VEGFR, VEGFR2 and VEGFR3 have the highest expression in tumors, while VEGFR1 and VEGFR4 have the lowest expression. The overexpression of VEGFR2 and VEGFR3 is an important reason for the occurrence and progression of many tumors, while the expression levels of VEGFR1 and VEGFR4 have an important impact on tumor progression and treatment response.

The role of VEGFR in the treatment of tumors, such as the treatment of breast cancer, lung cancer, gastrointestinal tumors, etc. During the treatment, anti-VEGF drugs are usually used, such as cisplatin, paclitaxel, doxorubicin, etc. These drugs can inhibit the VEGF signaling pathway, thereby inhibiting tumor growth. In addition, VEGF receptor antagonists, such as alitinib, bevacizumab, etc., are also widely used to treat tumors.

The role of VEGFR in disease treatment is still under further study. The role of VEGF and its receptors in neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, etc. In addition, the role of VEGF and its receptors in cardiovascular diseases, such as myocardial infarction, stroke, etc.

The role of VEGFR and its receptors in the treatment of tumors and cardiovascular diseases still requires further study.

Protein Name: Vascular Endothelial Growth Factor Receptor (VEGFR) (nonspecified Subtype)

More Common Targets